Published in AIDS Weekly, January 19th, 2004
An independent Data Safety Monitoring board (DSMB) has reviewed initial safety data for its first two patients and unanimously recommended that the trial continue without any modifications.
Lentiviral vectors have been shown to deliver genetic payloads stably into primary human cells with high efficiency, a necessary prerequisite for effective genetic therapy. The ongoing trial involves the use of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.